HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Cosmetic Adverse Event Data Beg Question: Mandatory Reporting?

This article was originally published in The Tan Sheet

Executive Summary

Legislation to update cosmetics oversight would require companies to report serious adverse events, which could propel numbers upward while providing FDA with greater insight to the marketplace. According to FDA data, cosmetic-related AERs in 2015 more than tripled from 2009, with consumers doing most reporting.

You may also be interested in...



Mandatory AE Reporting In Supplement Space Offers Glimpse Of Possible Cosmetic Future

Reports of serious adverse events in the dietary supplement industry have increased exponentially since reporting was made mandatory in 2008, and FDA warning letters citing failures to report have been on the rise as companies labor to keep up with investigations and reporting duties. Similar challenges could lie ahead for the cosmetics industry under proposed bills in the US House and Senate.

Feinstein, EWG Gunning For Spring Senate Hearing On Cosmetics Bill

During a March 1 press call, the Environmental Working Group highlighted findings from an 800-person survey indicating that 68% of men and women likely to vote this fall support increased government oversight of cosmetic chemicals. Senator Dianne Feinstein touted her proposed Personal Care Products Safety Act as the answer to consumer concerns, hopeful that a Senate committee hearing will be held in the spring.

FDA Cosmetics Update: 2013 AE Reports Tallied, 2014 Research Targeted

FDA says cosmetic-related adverse events were down in fiscal 2013, but suggests the decline may be due to a falloff in agency outreach and lower consumer awareness. The agency is focused on trace contaminants, with guidance in the works on lipstick lead, and aims to release its final guidance on cosmetic nanomaterials in the coming months, according to Linda Katz, director of FDA’s cosmetics office.

Topics

UsernamePublicRestriction

Register

RS108842

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel